Journal of Immunology Research

Journal of Immunology Research / 2018 / Article

Corrigendum | Open Access

Volume 2018 |Article ID 4154507 | 3 pages | https://doi.org/10.1155/2018/4154507

Corrigendum to “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China”

Received13 May 2018
Accepted29 May 2018
Published28 Jun 2018

In the article titled “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China” [1], there was an error in the value of the deceased patients, in the legend of Table 5, where “()” should be corrected to “().” The corrected table and its legend are shown below.


PhenotypeSexAge, yUnderlying diseaseSCORTENCulprit drugsTreatment

SJSM51Chronic renal failure, diabetes4AllopurinolSystemic steroids
TENM70Nil6AntibioticsSystemic steroids
TENF58Aneurysm, subarachnoid hemorrhageNAAntibioticsSystemic steroids
TENF67Rheumatic heart disease, mitral insufficiencyNAAntibiotics and compound with aminopyrine, phenacetin, caffeine, phenobarbitalSystemic steroids with IVIG use in the late stage
TENF71Coronary heart disease, hypertension, diabetes, diabetic nephropathy4Calcium dobesilateSystemic steroids with IVIG use in the early stage
TENM62Hypertension, diabetesNAAntibioticsSystemic steroids with IVIG use in the early stage
TENM94Coronary heart disease, cardiac insufficiency, hypertension, diabetes, interstitial lung diseaseNAAntibioticsSystemic steroids with IVIG use in the early stage
TENM62Hypertension, diabetes, chronic renal failure, hyperuricemiaNAAllopurinolSystemic steroids
TENM3Nil2AntibioticsSystemic steroids

IVIG use in the early stage ≤ 7 days of onset, IVIG use in the late stage ≥ 7 days of onset. NA: not available.

References

  1. S.-C. Yang, S. Hu, S.-Z. Zhang et al., “The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in China,” Journal of Immunology Research, vol. 2018, Article ID 4320195, 10 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2018 Shang-Chen Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

517 Views | 226 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.